Form 8-K - Current report:
SEC Accession No. 0001213900-23-010323
Filing Date
2023-02-10
Accepted
2023-02-10 16:35:37
Documents
14
Period of Report
2023-02-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea173123-8k_citiuspharma.htm   iXBRL 8-K 30486
2 PRESS RELEASE, DATED FEBRUARY 10, 2023 ea173123ex99-1_citiuspharma.htm EX-99.1 76941
3 GRAPHIC ex99-1_001.jpg GRAPHIC 13247
  Complete submission text file 0001213900-23-010323.txt   310877

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ctxr-20230210.xsd EX-101.SCH 3239
5 XBRL LABEL FILE ctxr-20230210_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE ctxr-20230210_pre.xml EX-101.PRE 22367
8 EXTRACTED XBRL INSTANCE DOCUMENT ea173123-8k_citiuspharma_htm.xml XML 3601
Mailing Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016
Business Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016 (908) 967-6676
Citius Pharmaceuticals, Inc. (Filer) CIK: 0001506251 (see all company filings)

EIN.: 273425913 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-38174 | Film No.: 23612684
SIC: 2834 Pharmaceutical Preparations